00:16:15 Europe / Stockholm

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamma inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget är verksamma inom den skandinaviska marknaden. Newbury Pharmaceuticals har sitt huvudkontor i Lund.

Kalender

2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2

Prenumeration

2021-12-10 14:00:00

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the oncology portfolio with the addition of Lapatinib. Lapatinib is a targeted cancer drug, also known by its brand name Tyverb®, that is used to treat certain type of breast cancers, whose tumours overexpress HER2.

“Lapatinib is a terrific supplement to the existing high-value product portfolio and we are proud to further strengthen our commitment within oncology” says Mr Lars Minor CEO of Newbury
 
Newbury currently has eleven (11) products within oncology and providing treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer, NSCLC and thyroid cancer).
 
Regulatory filling will take place during the next few years, and we aim to be among the first to launch many of these medicines in Scandinavia where the total annual value of this market is estimated to be 400 MEUR according to DLMI Nordic Pharma Insights.
 
”Newbury is a start-up with high ambitions and  we are rapidly growing our portfolio within our focus areas of oncology, rare diseases and neurology. We want to be known to make a difference within these therapeutic areas” says Karl Karlsson Founder & Chairman